---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-003196"
form_type: "8-K"
ticker: null
cik: "0001444380"
company_name: "NEVRO CORP"
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:25:42.793998+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nevro Q4 prelim revenue $116M (+2% YoY) beats expectations; cuts 5% of staff

## Summary
- Preliminary Q4 2023 worldwide revenue ~$116.0M, up 2% YoY, exceeding company expectations.
- Full-year 2023 revenue ~$425.0M (+5% YoY); PDN sales $77.9M (+63% YoY).
- Restructuring approved: lay off 63 employees (5% workforce), mainly internal roles.
- Expects $14M-$15M positive impact on 2024 adjusted EBITDA; $5M-$6M charge in Q1 2024.

## SEC filing metadata
- accession: 0000950170-24-003196
- form_type: 8-K
- cik: 0001444380
- company_name: NEVRO CORP
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/nvro-20240106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-003196
- JSON: https://secwatch.observer/filing/0000950170-24-003196.json
- Plain text: https://secwatch.observer/filing/0000950170-24-003196.txt

## Key facts
- Earnings Releases
  NEVRO CORP reported preliminary financial results for fourth quarter and full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Result: preliminary results
  source text: On January 9, 2024, Nevro Corp. ("Nevro" or the "Company") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm
- Restructurings & Charges
  NEVRO CORP announced a restructuring with charges of $5 million to $6 million restructuring charge affecting corporate, sales and marketing, and operations positions but largely focused on internally facing roles (63 employees, which represented approximately 5% of the Company’s total number of employees).
  - Type: restructuring
  - Charge: $5 million to $6 million restructuring charge
  - Affected area: corporate, sales and marketing, and operations positions but largely focused on internally facing roles
  - Headcount: 63 employees, which represented approximately 5% of the Company’s total number of employees
  source text: expense increases, including inflation, merit increases and other acquisition-related expenses. In addition, GAAP operating expenses in the first quarter of 2024 will reflect a $5 million to $6 million restructuring charge, consisting of one-time severance and other termination benefit costs. The Company expects that the Restructuring, including related cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.